Clinical Trial

Polypharmacy, Safety, and Medication Adherence in Patients With Chronic Heart Failure With Reduced and Mildly Reduced Ejection Fraction

Study acronym: FARAON
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This prospective registry study (FARAON) aims to assess the prevalence, structure, safety profile, and dynamics of polypharmacy, as well as its association with medication adherence, quality of life, and clinical outcomes in multimorbid patients with HFrEF and HFmrEF, aiming to identify potentially inappropriate prescribing (over/mis/underprescribing) and determine factors linked to low adherence and adverse events.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-05.
Trial Details
NCT Number NCT07640854
Lead Sponsor National Medical Research Center for Therapy and Preventive Medicine
Conditions Chronic Heart Failure With Reduced and Mildly Reduced Ejection Fraction (HFrEF and HFmrEF)
Enrollment 130 participants
Start Date 2026-01-20
Primary Completion 2027-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-16